ДИАГНОСТИКА, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА И ЛЕЧЕНИЕ БРОНХООБСТРУКТИВНОГО СИНДРОМА: МЕСТО КОМБИНИРОВАННЫХ ПРЕПАРАТОВ Β2-АГОНИСТОВ И ИНГАЛЯЦИОННЫХ ГЛЮКОКОРТИКОСТЕРОИДОВ
https://doi.org/10.18093/0869-0189-2011-0-1-89-98
Аннотация
Диагностика, дифференциальная диагностика и лечение бронхообструктивного синдрома: место комбинированных препаратов β2-агонистов и ингаляционных глюкокортикостероидов
Об авторе
А. Р. Татарский
ГОУ ВПО "Российский государственный медицинский университет им. Н.И.Пирогова"
Россия
Россия
д. м. н., проф. кафедры госпитальной терапии педиатрического факультета
117997, Москва, ул. Островитянова, 1.
Тел.: (495) 465-52-64.
Список литературы
1. Global initiative for asthma. Global Strategy for Asthma Management and Prevention Update 2009: www.gin asthma.org
2. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease.NHLBI / WHO workshop report / Last update 2009. www.goldcopd.org
3. Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.
4. Chetta A., Zanini A., Foresi A. et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5):751–757.
5. Hoshino M.Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.
6. Lundbäck B., Rönmark E., Lindberg A. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100(1): 2–10.
7. Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A.The burden of asthma in Australia. Med. J. Aust. 2001; 175(3): 141–145.
8. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guide line-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.
9. Mahler D.A. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease.J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.
10. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002;166 (8): 1084–1091.
11. Vestbo J., Pauwels R., Anderson J.A. et al. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301–304.
12. Vestbo J. New thinking and COPD. Ugeskr. Laeg. 2003; 165 (45): 4319.
13. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur.Respir. J. 2004; 24 (2): 206–210.
14. Calverley P.M., Anderson J.A., Celli B. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.2007; 356 (8): 775–789.
15. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1):19–26.
16. Jenkins C.R., Jones P.W., Calverley P.M. et al. Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res.2009; 10: 59.
17. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361 (9356): 449–456. Erratum in: Lancet 2003; 361(9369): 1660.
18. Calverley P.M., Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362 (9389): 1053–1061.
19. Vestbo J., Pauwels R., Anderson J.A. et al. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60 (4): 301–304.
20. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4):332–338.
21. Calverley P.M., Anderson J.A., Celli B. et al. Cardiovascular events in patients with COPD: TORCH study results.Thorax 2010; 65 (8): 719–725.
22. Welte T. Inhaled corticosteroids in COPD and the risk ofpneumonia. Lancet 2009; 374 (9691): 668–670.
23. Singh S., Loke Y.K. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int. J. COPD 2010; 5: 189–195.
24. Drummond M. B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease a systematic review and meta-analysis.J.A.M.A. 2008; 300 (20): 2407–2416.
25. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
Рецензия
Для цитирования:
Татарский А.Р. ДИАГНОСТИКА, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА И ЛЕЧЕНИЕ БРОНХООБСТРУКТИВНОГО СИНДРОМА: МЕСТО КОМБИНИРОВАННЫХ ПРЕПАРАТОВ Β2-АГОНИСТОВ И ИНГАЛЯЦИОННЫХ ГЛЮКОКОРТИКОСТЕРОИДОВ. Пульмонология. 2011;(1):89-98. https://doi.org/10.18093/0869-0189-2011-0-1-89-98
For citation:
Tatarsky A.R. DIAGNOSIS, DIFFERENTIATION AND MANAGEMENT OF BRONCHIAL OBSTRUCTIVE SYNDROME: A ROLE OF Β2-AGONISTS AND INHALED STEROIDS COMBINED IN A SINGLE INHALER. PULMONOLOGIYA. 2011;(1):89-98. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-1-89-98
Просмотров:
934
Послать статью по эл. почте 